CERO Key Statistics, Chart & Performance
The current stock price of CERO is 0.0951 USD. In the past month the price decreased by -98.24%. In the past year, price decreased by -99.94%.
CERO Latest News, Press Relases and Analysis
CERO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About CERO
Company Profile
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Company Info
CERO THERAPEUTICS HOLDINGS I
201 Haskins Way, Suite 230
South San Francisco CALIFORNIA US
Employees: 8
Phone: 6504072376
CERO THERAPEUTICS HOLDINGS I / CERO FAQ
What does CERO do?
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
What is the stock price of CERO THERAPEUTICS HOLDINGS I today?
The current stock price of CERO is 0.0951 USD. The price decreased by -94.69% in the last trading session.
Does CERO stock pay dividends?
CERO does not pay a dividend.
How is the ChartMill rating for CERO THERAPEUTICS HOLDINGS I?
CERO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of CERO stock?
CERO THERAPEUTICS HOLDINGS I (CERO) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of CERO THERAPEUTICS HOLDINGS I (CERO) based on its PE ratio?
CERO THERAPEUTICS HOLDINGS I (CERO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-223.77).
CERO Technical Analysis
CERO Financial Highlights
Over the last trailing twelve months CERO reported a non-GAAP Earnings per Share(EPS) of -223.77. The EPS increased by 63.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -675.76% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CERO Forecast & Estimates
8 analysts have analysed CERO and the average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.